Abstract
The Cancer Prevention & Research Institute of Texas is supporting 16 Texas institutions with more than $177 million. Three grants, totaling more than $50 million, are heading to a trio of biotech firms. Forbius will receive nearly $19 million to evaluate an anti-EGFR antibody-drug conjugate in Phase IIa clinical trials. Korysso Therapeutics will receive nearly $20 million to develop compounds that treat neurological damage caused by cancer chemotherapy. And CerRx will receive nearly $12 million to test combination drug therapies in lymphoma.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
